Trial Profile
A Phase II, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intravitreal Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Oct 2014
Price :
$35
*
At a glance
- Drugs Bevasiranib (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors OPKO Health
- 09 Oct 2014 New trial record